Press release
Alpha-1 Antitrypsin Deficiency Treatment Market Size 2025-2033
The alpha-1 antitrypsin deficiency market is witnessing significant growth, driven by increasing awareness and advancements in diagnostic techniques. AATD is a genetic disorder characterized by low levels or malfunctioning of the alpha-1 antitrypsin protein, leading to heightened risks of lung and liver diseases. In 2023, the market across seven major regions was valued at USD 1.4 million. Projections indicate a robust growth trajectory, with expectations to reach USD 3.9 million by 2034, reflecting a compound annual growth rate (CAGR) of 9.83% during the forecast period.Request for a sample copy of this report:
https://www.imarcgroup.com/alpha-1-antitrypsin-deficiency-market/requestsample
Study Assumption Years
• Base Year: 2023
• Historical Years: 2018-2023
• Forecast Years: 2024-2034
Alpha-1 Antitrypsin Deficiency Market Key Takeaways
• Market Size & Growth: The AATD market was valued at USD 1.4 million in 2023 and is projected to reach USD 3.9 million by 2034, growing at a CAGR of 9.83%.
• Regional Dominance: The United States holds the largest patient pool and represents the most significant market for AATD treatment.
• Therapeutic Advancements: Augmentation therapy, involving regular intravenous infusions of purified alpha-1 antitrypsin protein, is widely adopted to protect lungs from protease enzyme imbalance.
• Diagnostic Improvements: Enhanced diagnostic methods, including genetic testing for SERPINA1 gene mutations, are facilitating early and accurate detection of AATD.
• Research & Development: Key players are investing in R&D to develop disease-modifying therapies aimed at reducing misfolded protein accumulation and enhancing clearance of abnormal protein aggregates.
• Genetic Testing Expansion: The use of expanded genetic panels is gaining popularity, allowing identification of rare or novel mutations, thereby improving diagnostic accuracy.
• Pulmonary Rehabilitation: Increasing utilization of pulmonary rehabilitation programs is aiding in improving lung function and overall respiratory health among AATD patients.
Market Growth Factors
1. Alpha-1 antitrypsin deficiency treatment market growth
The Alpha-1 Antitrypsin Deficiency (AATD) treatment market is experiencing significant growth, driven by a combination of factors. A key driver is the increasing awareness and diagnosis rates of the disease, which is often underdiagnosed. Enhanced screening programs, including those for newborns and individuals with COPD, are leading to earlier and more frequent identification of AATD patients.
2. Rising demand for COPD and emphysema therapies in AATD patients
The treatment landscape for Alpha-1 antitrypsin deficiency (AATD) is increasingly focused on managing its most common and devastating manifestation: lung disease, specifically COPD and emphysema. As awareness of AATD grows and diagnostic methods improve, there's a rising demand for therapies that can effectively slow the progression of lung damage. The cornerstone of AATD-specific treatment is augmentation therapy, which involves weekly or biweekly infusions of a human plasma-derived protein. This treatment aims to raise the protective level of the alpha-1 antitrypsin protein in the lungs, thereby inhibiting the elastase enzyme that causes tissue destruction.
3. Growing demand for liver disease management in AATD patients
The management of liver disease in patients with Alpha-1 Antitrypsin Deficiency (AATD) is a growing concern, driven by increasing awareness and a better understanding of the condition's dual impact on both the lungs and liver. While augmentation therapy exists for lung-related AATD, there is currently no specific treatment to prevent the accumulation of the misfolded protein that causes liver damage. This has led to a rising demand for comprehensive care focused on monitoring, symptom management, and risk reduction.
Request for a sample copy of this report:
https://www.imarcgroup.com/alpha-1-antitrypsin-deficiency-market/requestsample
Market Segmentation
Breakup by Region:
o North America (United States, Canada)
o Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
o Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
o Latin America (Brazil, Mexico, Others)
o Middle East and Africa
Regional Insights
The United States really stands out as the top market for treating alpha-1 antitrypsin deficiency, thanks to its large patient base and cutting-edge healthcare system. The focus on early diagnosis, the widespread use of augmentation therapy, and significant investments in research and development are all driving the growth of this market. Plus, with major pharmaceutical companies in the mix and supportive reimbursement policies, the U.S. is solidifying its strong position in the global AATD scene.
Recent Developments & News
The alpha-1 antitrypsin deficiency market is buzzing with recent advancements, particularly thanks to significant investments in research and development aimed at bringing disease-modifying therapies to life. These therapies are all about reducing the buildup of misfolded alpha-1 antitrypsin protein in cells and improving the clearance of those pesky abnormal protein aggregates. Plus, the growing trend of using expanded genetic panels is exciting, as they help identify rare or novel mutations, which in turn enhances the accuracy of genetic diagnoses. All these developments are fostering a hopeful outlook for the market, signalling a move towards more personalized and effective treatment options for AATD patients.
Key Players
Grifols, Kamada, CSL Behring, Arrowhead Pharmaceuticals, Takeda Pharmaceuticals USA, Inhibrx, Vertex Pharmaceuticals, Dicerna Pharmaceuticals.
Ask Analyst for Customization:
https://www.imarcgroup.com/request?type=report&id=7844&flag=C
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as part of the customization.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: (+1-201971-6302)
IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include a thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape, and benchmarking analyses, pricing and cost research, and procurement research.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Alpha-1 Antitrypsin Deficiency Treatment Market Size 2025-2033 here
News-ID: 4173635 • Views: …
More Releases from IMARC Group

Electric Bus Manufacturing Plant Setup Cost 2025: Feasibility and Profitability …
Setting up an electric bus manufacturing facility necessitates a detailed market analysis alongside granular insights into various operational aspects, including unit processes, raw material procurement, utility provisions, infrastructure setup, machinery and technology specifications, workforce planning, logistics, and financial considerations.
IMARC Group's report titled "Electric Bus Manufacturing Plant Project Report 2025: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue" offers a comprehensive guide for establishing an electric bus…

Global School Furniture Market Thrives Amid Rising Demand for Modern and Ergonom …
School Furniture Market Overview
The global school furniture market is steadily expanding, driven by the establishment of new educational institutions, the growing need for ergonomic and student-focused designs, and the increasing use of online platforms for procuring educational equipment. In 2024, the market stood at USD 5.2 billion and is expected to reach USD 8.6 billion by 2033, registering a compound annual growth rate (CAGR) of 5.47% from 2025 to 2033.
Additionally,…

Global Game-Based Learning Market Surges as EdTech Innovation Transforms Educati …
Game-Based Learning Market Overview
The global game-based learning market is experiencing remarkable growth, driven by the rising demand for interactive, engaging, and immersive educational experiences. In 2024, the market reached a valuation of USD 21.3 billion and is projected to hit USD 80.0 billion by 2033, expanding at a CAGR of 15.05%. Factors such as increasing smartphone penetration, a shift toward personalized learning, and the integration of immersive technologies across schools,…

Rock Wool Insulation Manufacturing Plant Setup Cost 2025: Layout and Raw Materia …
Setting up a Rock wool insulation manufacturing facility necessitates a detailed market analysis alongside granular insights into various operational aspects, including unit processes, raw material procurement, utility provisions, infrastructure setup, machinery and technology specifications, workforce planning, logistics, and financial considerations.
IMARC Group's report titled "Rock Wool Insulation Manufacturing Plant Project Report 2025: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue" offers a comprehensive guide for establishing a…
More Releases for AATD
Alpha-1 Antitrypsin Deficiency (AATD) Market Emerging Trends and Growth Prospect …
Introduction
Alpha-1 Antitrypsin Deficiency (AATD) is a rare genetic disorder that can cause progressive lung conditions such as emphysema, chronic obstructive pulmonary disease (COPD), and liver disease including cirrhosis and hepatocellular carcinoma. With growing awareness, advancements in genetic testing, and a rising focus on orphan drug development, the AATD market is entering a transformative phase.
By combining established augmentation therapies with innovative approaches such as gene therapy and RNA interference (RNAi) therapeutics,…
Alpha-1 Antitrypsin Deficiency (AATD) Market Set to Witness Significant Growth b …
Introduction
Alpha-1 Antitrypsin Deficiency (AATD) is a rare genetic disorder caused by mutations in the SERPINA1 gene, leading to low levels or dysfunction of the alpha-1 antitrypsin (AAT) protein. This protein protects tissues from enzyme-related damage, and its deficiency predisposes patients to early-onset emphysema, chronic obstructive pulmonary disease (COPD), liver disease, and, in some cases, skin problems such as panniculitis.
Historically, augmentation therapy using plasma-derived AAT has been the standard treatment to…
Alpha-1 Antitrypsin Deficiency (AATD) Market New Product Development & Latest Tr …
Introduction
Alpha-1 antitrypsin deficiency (AATD) is a rare genetic disorder caused by mutations in the SERPINA1 gene, leading to low levels of the alpha-1 antitrypsin (AAT) protein. This protein normally protects the lungs from neutrophil elastase; deficiency results in early-onset chronic obstructive pulmonary disease (COPD), emphysema, and liver disease.
Despite affecting an estimated 1 in 2,500-5,000 people of European descent, AATD is significantly underdiagnosed due to overlapping symptoms with asthma and COPD.…
Alpha-1 Antitrypsin Deficiency Pipeline: 40+ Pioneering Companies Driving Innova …
The Alpha-1 antitrypsin deficiency market is entering a new era of innovation, driven by over 20 leading biotech and pharma players, including Intellia Therapeutics, Apic Bio, Linton Pharm, Z Factor Limited, Vertex Pharmaceuticals, Grifols, and Kamada. These visionaries are reshaping treatment paradigms with next-gen therapies that promise greater precision and better outcomes.
DelveInsight's "Alpha-1 Antitrypsin Deficiency Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Alpha-1…
Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue, Trend …
New York, United States, -
The Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market size is estimated to grow at a CAGR of 6.2% between 2023 and 2032. The growth of the market depends on several factors, including the increasing prevalence of Alpha-1 Antitrypsin Deficiency, advancements in treatment options, and rising awareness about this genetic disorder. Alpha-1 Antitrypsin Deficiency is a genetic condition that can lead to lung and liver…
Globally, More than 12+ Companies are Developing 12+ Therapies in Alpha1-Antitry …
"Alpha-1 Antitrypsin Deficiency Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Alpha-1 Antitrypsin Deficiency Therapeutics Market.
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the…